http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020519296-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020519296-A |
| titleOfInvention | DNA methylation and mutation analysis method for bladder cancer monitoring |
| abstract | The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for the presence of methylated DNA and optionally specific gene mutations. In some embodiments, the analysis result correlates with a clinical endpoint such as bladder cancer recurrence risk. The above-described method includes, for example, obtaining a urine sediment sample from a patient; converting DNA derived from the sample into bisulfite; , ONECUT2, KLF2, OSR1, SOX1, EOMES, DDX25, and TMEM106A, and determining the amount and/or concentration of methylated DNA in the sample from a set of genes comprising at least four genes. .. |
| priorityDate | 2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 111.